Who
Emily Fairbairn
Director
Company insider
Files Form 4 as: Director, Corvex; Director and 10% owner, IN8bio.
In numbers
- Trades disclosed
- 66
- Buys
- 9
- Sells
- 0
- Bought
- $1.1M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 23 Mar 2021
- Last trade
- 7 Jul 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 8 Jul 2026 | MOVE CorvexPayments & Processors | SEC FORM 4 Code C | —1,205,282 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | MOVE Corvexoption or derivative · Payments & Processors | SEC FORM 4 Code C | —1,205.283 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | MOVE Corvexoption or derivative · Payments & Processors | SEC FORM 4 Code C | —1,205.28 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | MOVE CorvexPayments & Processors | SEC FORM 4 Code C | —1,205,282 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MOVE CorvexPayments & Processors | SEC FORM 4 Code A | —135,800 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MOVE Corvexoption or derivative · Payments & Processors | SEC FORM 4 Code D | —858.54 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MOVE Corvexoption or derivative · Payments & Processors | SEC FORM 4 Code A | —858.54 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MOVE Corvexoption or derivative · Payments & Processors | SEC FORM 4 Code D | —858.54 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MOVE Corvexoption or derivative · Payments & Processors | SEC FORM 4 Code A | —858.54 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MOVE CorvexPayments & Processors | SEC FORM 4 Code A | —135,800 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | INAB IN8bioBiotechnology | SEC FORM 4 Code G | —724,637 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | INAB IN8bioBiotechnology | SEC FORM 4 Code G | —724,637 at $0.00 | filing |
| 9 May 2026filed 12 May 2026 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 9 May 2026filed 12 May 2026 | INAB IN8biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | MOVE CorvexPayments & Processors | SEC FORM 4 Code C | —9,231 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | MOVE Corvexoption or derivative · Payments & Processors | SEC FORM 4 Code C | —9.232 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | MOVE Corvexoption or derivative · Payments & Processors | SEC FORM 4 Code C | —9.23 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | MOVE CorvexPayments & Processors | SEC FORM 4 Code C | —9,231 at $0.00 | filing |
| 19 Mar 2026filed 19 Mar 2026 | MOVE Corvexoption or derivative · Payments & Processors | SEC FORM 4 Code A | —9.232 at $0.00 | filing |
| 19 Mar 2026filed 19 Mar 2026 | MOVE Corvexoption or derivative · Payments & Processors | SEC FORM 4 Code A | —2,063.823 at $0.00 | filing |
News
Critical Analysis: Corvex (NASDAQ:MOVE) versus Backblaze (NASDAQ:BLZE)MOVE · tickerreport.com · 15 Oct 2026Head-To-Head Comparison: Corvex (NASDAQ:MOVE) vs. Nomura Research Institute (OTCMKTS:NRILY)MOVE · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Emily Fairbairn; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.